Welcome to our dedicated page for CollPlant Biotechnologies Ordinary Shares news (Ticker: CLGN), a resource for investors and traders seeking the latest updates and insights on CollPlant Biotechnologies Ordinary Shares stock.
CollPlant Biotechnologies Ltd (NASDAQ: CLGN) is a pioneering company in regenerative and aesthetic medicine, specializing in the 3D bioprinting of tissues and organs and medical aesthetics. The company's core technology is its recombinant human collagen (rhCollagen), produced through proprietary plant-based genetic engineering. CollPlant's innovative products address diverse fields of tissue repair, aesthetics, and organ manufacturing, marking a new era in regenerative medicine.
CollPlant's flagship rhCollagen bioink product line is optimized for 3D bioprinting applications, including drug discovery, tissue testing, and the development of transplantable tissues and organs. The company's unique Vergenix™ line includes a soft tissue repair matrix for tendinopathy treatment and a wound repair matrix that promotes rapid healing of acute and chronic wounds.
In the medical aesthetics market, CollPlant is advancing its regenerative breast implants and dermal fillers. The company has formed strategic partnerships, including a notable collaboration with AbbVie for the development of dermal and soft tissue fillers, triggering milestone payments and potential future royalties.
Recent achievements include the initiation of pre-clinical trials for regenerative breast implants and progress in large-animal studies demonstrating tissue regeneration and safety. In addition, CollPlant's advanced bioinks are facilitating the bio-fabrication of human tissues and organs in collaboration with industry leaders.
Financially, CollPlant reported significant revenue increases due to milestone payments and product sales, although it continues to invest in research and development to maintain its leading position in the market. The company's cash and cash equivalents provide a robust runway for at least two years of operation, supporting ongoing and future projects.
CollPlant's commitment to sustainability is reflected in its plant-based production process and adherence to Environmental, Social, and Governance (ESG) principles. The company joined the United Nations Global Compact to further its sustainable corporate governance goals.
CollPlant (NASDAQ: CLGN) is set to present at the TERMIS conference in Toronto, Canada from July 10-13, 2022. The company will showcase its revolutionary rhCollagen technology through two presentations: "RhCollagen - The Ideal Building Block For 3D Printed and Injectable Scaffolds for Regenerative Medicine" on July 13, and a poster on "Recombinant Human Collagen-Based Bioinks for Biofabrication Applications" on July 11. CollPlant focuses on advanced regenerative medicine, highlighting its innovative biomaterials aimed at tissue repair, bioprinting, and skin rejuvenation.
CollPlant (Nasdaq: CLGN) announced the initiation of a large animal study for its 3D bioprinted regenerative breast implants, targeting the $2.8 billion global breast implant market. This study aims to evaluate the implants' performance, including tissue regeneration and integration and is expected to conclude within six months. CollPlant's technology utilizes plant-derived rhCollagen, which aims to reduce safety issues linked to silicone implants. The company plans to follow this study with human trials, marking significant progress in their product development.
CollPlant Biotechnologies (NASDAQ: CLGN) reported updates on its strategic initiatives and Q1 2022 financial results. The company is advancing its collaboration with AbbVie to develop rhCollagen-based dermal fillers and is on track to initiate a large animal study for its 3D bioprinted breast implant program in Q2 2022. As of March 31, 2022, CollPlant had cash and equivalents of $41M. Q1 revenues declined to $66,000, down from $14.5M year-over-year, largely due to a $14M upfront payment from AbbVie in 2021. The GAAP net loss was $3.9M, or $0.36 per share.
CollPlant (Nasdaq: CLGN) announced that CEO Yehiel Tal will moderate a virtual event hosted by the International Society for Biofabrication (ISBF) on May 2, 2022. The event, titled Biofabrication of Microphysiological Systems for Drug Discovery and Screening, aims to enhance collaboration across academia and industry, featuring experts from notable institutions. This engagement reflects CollPlant's commitment to advancing regenerative medicine through innovative technologies.
CollPlant (NASDAQ: CLGN), a leader in regenerative medicine, announced that Dr. Jasmine Seror will present at the Aesthetics Innovation Summit 2022 on April 20, 2022. Her presentation, titled "Novel photocurable rhCollagen implants for regenerative aesthetics applications," will be featured during the spotlight session at 11:20 AM EST. CollPlant focuses on innovative technologies utilizing rhCollagen, aimed at enhancing tissue regeneration and organ manufacturing.
CollPlant Biotechnologies (NASDAQ: CLGN) announced its fiscal year 2021 results, highlighting a significant GAAP revenue increase of 156%, reaching $15.6 million, primarily driven by a $14 million upfront payment from AbbVie. Gross profit surged 339% to $13.6 million. Operating expenses rose to $13.6 million, reflecting increased R&D and personnel costs. The company achieved a net income of $237,000, or $0.02 per share, contrasting with a net loss of $5.8 million in 2020. CollPlant plans to initiate a large animal study for its 3D bioprinted breast implant program in Q2 2022, targeting a market worth $2.8 billion.
CollPlant Biotechnologies and CELLINK announced a collaboration agreement on Feb. 16, 2022, to develop large-scale production of regenerative breast implants using CELLINK's 3D bioprinting technology. This collaboration targets a market worth $2.8 billion with approximately 2.2 million procedures conducted annually. CollPlant has produced prototypes of these implants, designed to naturally regenerate breast tissue. CELLINK's expertise in biofabrication is expected to assist in overcoming production challenges, aiming for commercialization to provide essential solutions for patients worldwide.
RION, a biotechnology company based in Rochester, Minnesota, has appointed Alisa Lask as Chief Commercial Officer. Lask brings extensive experience from leadership roles at major firms including Galderma and Allergan, aiming to commercially leverage RION's groundbreaking exosome therapeutics. The company currently has two active FDA registrations and focuses on innovative biologic platforms for regenerative medicine. Dr. Atta Behfar, RION's founder, expressed confidence in Lask's strategic vision to drive growth in both therapeutic and aesthetic sectors.
CollPlant Biotechnologies (Nasdaq: CLGN) recently shared a CEO letter detailing significant advancements in 2021. Key collaborations include partnerships with Allergan for dermal fillers and 3D Systems for breast reconstruction matrices. The company's revenues skyrocketed to $15.3 million, supported by a $14 million payment from AbbVie. Operational costs were managed, with R&D expenses at $5.4 million. CollPlant is enhancing its production capabilities and expanding its IP portfolio. The firm aims to lead in regenerative medicine and plans to launch more innovative products in the near future.
CollPlant announced the publication of an article in the Plastic and Reconstructive Surgery journal showcasing its photocurable dermal filler. The filler demonstrated enhanced lifting effects and improved tissue regeneration in preclinical models compared to standard options. Composed of recombinant human collagen, the filler aims to provide efficient contour corrections. The company continues to forge partnerships for product development, including collaborations with Allergan and 3D Systems for broader applications in regenerative medicine.
FAQ
What is the current stock price of CollPlant Biotechnologies Ordinary Shares (CLGN)?
What is the market cap of CollPlant Biotechnologies Ordinary Shares (CLGN)?
What does CollPlant Biotechnologies Ltd do?
What is rhCollagen?
What are CollPlant's main products?
What are the recent achievements of CollPlant?
Who are CollPlant's strategic partners?
Where does CollPlant operate?
What are CollPlant's financial highlights?
How is CollPlant contributing to sustainability?
What is the market potential for CollPlant's products?
How can investors participate in CollPlant's conference calls?
